Lemtrada Side Effects Range From Drug-Induced Autoimmune Complications To Cardiovascular Reactions
Medical researchers in Switzerland recently presented the case of a 26-year-old man who developed life-threatening anti-neutrophil cytoplasmic autoantibody (ANCA) systemic vasculitis after being treated with Lemtrada (alemtuzumab) for relapsing-remitting multiple sclerosis. This case report about Lemtrada causing ANCA-associated vasculitis adds to the growing number of autoimmune complications which can be regarded as Lemtrada side effects.
This medical article about Lemtrada, "ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis", was published February 21, 2020 by the Multiple Sclerosis Journal. From the Abstract for this article:
Lemtrada (alemtuzumab) is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. In contrast to rare cases of immune-mediated cutaneous vasculitis, systemic vasculitis after alemtuzumab has not yet been described. We report the case of a 29-year-old man with RRMS who developed fever, auricular chondritis, cutaneous vasculitis and life-threatening diffuse alveolar haemorrhage, 12 months after Lemtrada (alemtuzumab). Antibodies to myeloperoxidase appeared 9 months after Lemtrada (alemtuzumab) and were extremely high at the time of vasculitis. Outcome was favourable after glucocorticoids, plasma exchanges and rituximab. Thus, Lemtrada (alemtuzumab) may induce life-threatening vasculitis in patients treated for RRMS.
Strictly Confidential, No Obligation.
Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis is an autoimmune disease that causes blood vessels to swell. Several types of ANCA vasculitis exist due to numerous causes, so patients diagnosed with ANCA vasculitis may display varied symptoms.
We have written several articles about Lemtrada side effects over the past couple of years, with the most recent one being "Lemtrada Cardiovascular Reactions Can Occur Within 1-3 Days Of Infusions In People Without Any Identifiable Risk Factors", which we posted in March 2020.
We will monitor the medical literature for possible other reports of Lemtrada causing ANCA-associated vasculitis as well as other more well-established Lemtrada side effects.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)